Oncology Acute Care Follow-up Intervention Study

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT07550192
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Follow-up messaging — OTHER
    Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).

Study Details

This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health. Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends. After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.

Key Dates

Start date
May 15, 2026
Status verified
Apr 2026
Primary completion
May 15, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • No Intervention: Control Arm (Usual Care)
    Patients receive standard hospital discharge instructions without additional messaging Patients in the control arm who experience a subsequent cancer treatment-related ED visit without documented OAC engagement will be crossed over to the intervention arm.
  • Experimental: Intervention Arm
    Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge.

Primary Outcome Measure

Time to the next cancer treatment related ED visit. [ Time Frame: 2 years maximum ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Parkland HealthDallasTexas75235
Arthur Hong, MD
[email protected]
214-648-3240
Kathryn Anderson, MA
[email protected]
214-648-6357

Find similar trials in Dallas, TX

By research site
Parkland Health· Dallas, TX

Related Studies